I highly recommend a subscription to Pharmacist's Letter. It summarizes the newest info very well.
Pharmacist's Letter Canada recently released an article as part of their July 2017 newsletter.
They have actually released it for free public viewing:
If you want the short version here it is:
"Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds."
"So far, this has only been seen with canagliflozin. But a class effect can’t be ruled out yet with the other flozins...dapagliflozin (Forxiga, etc) or empagliflozin (Jardiance, etc)."
"Advise patients to contact their prescriber immediately if they develop new foot pain or tenderness, sores or ulcers, etc."
News that has been personally selected by the Editorial team.